Complement interactions with amyloid-β1-42: A nidus for inflammation in AD brains

Amyloid

Volumn 4, Issue 3, 1997, Pages 147-156

  Watson, M Desiree ^a   Roher, Alex E ^b   Kim, K S ^c   Spiegel, Katharyn ^a   Emmerling, Mark R ^a  

^a PFIZER INC   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Alzheimer's disease; Anaphylatoxin; C3 convertase; Inflammation; Microglia; Opsonization; Phagocytosis

Indexed keywords

EID: 0000911605     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129709014379     Document Type: Article

References (54)

1. McPhaden AR and Whaley K, The Complement System and Inflammation. Immunology and Medicine Series, ed. K. Whaley. Vol. 18. 1992, Dordrecht: Kluwer Academic Publishers. 17-36
2. Law SK, Minich TM and Levine RP (1981). Binding reaction between the third human complement protein and small molecules. Biochemistry 20, 7457-7463
3. Law SK, Lichtenberg NA and Levine RP (1979). Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 123, 1388-1394
4. Morgan BP (1989). Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 264, 1-14
5. McGeer PL, McGeer EG, Kawamata T, Yamada T and Akiyama H (1991). Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 18, 376-379
6. Rogers J, Webster S, Lue L-F, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D and McGeer P (1996). Inflammation and Alzheimer's Disease pathogenesis. Neurobiol Aging 17, 681-686
7. Eikelenboom P and Veerhuis R (1996). The role of complement and activated microglia in the pathogenesis of Alzheimer's Disease. Neurobiol Aging 17, 673-680
8. Veerhuis R, van der Valk P, Janssen I, Zhan SS, Van Nostrand WE and Eikelenboom P (1995). Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch 426, 603-610
9. Rozemuller JM, Stam FC and Eikelenboom P (1990). Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 119, 75-78
10. Eikelenboom P, Rozemuller JM, Kraal G, Stam FC, McBride PA, Bruce ME and Fraser H (1991). Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B Cell Pathol Incl Mol Pathol 60, 329-336
11. Brachova L, Lue LF, Schultz J, el Rashidy T and Rogers J (1993). Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Brain Res Mol Brain Res 18, 329-334
12. Afagh A, Cummings BJ, Cribbs DH, Cotman CW and Tenner AJ (1996). Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol 138, 22-32
13. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P and Lieberberg I (1992). Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci 89, 10016-10020
14. Jiang H, Burdick D, Glabe CG, Cotman CW and Tenner AJ (1994). Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1qA chain. J Immunol 152, 5050-5059
15. Lue L-E, Brachova L, Civin H and Rogers J (1996). Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's Disease neurodegeneration. J Neuropath Exp Neurol 55, 1083-1088
16. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Cowing E and Ball MJ (1993). β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci 90, 10836-10840
17. Fukumoto H, Asami Odaka A, Suzuki N and Iwatsubo T (1996). Association of Aβ40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Neurodegeneration 5, 13-17
18. Mann DM, Iwatsubo T, Fukumoto H, Ihara Y, Odaka A and Suzuki N (1995). Microglial cells and amyloid beta protein (Aβ) deposition; association with Aβ 40-containing plaques. Acta Neuropathol Berl 90, 472-477
19. Walker DG, Kim SU and McGeer PL (1995). Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 40, 478-93
20. Gasque P, Fontaine M and Morgan BP (1995). Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 154, 4726-33
21. Barnum SR (1995). Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 6, 132-146
22. Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND and Jasani B (1989). Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 15, 307-316
23. Rozovsky I, Morgan TE, Willoughby DA, Dugichi Djordjevich MM, Pasinetti GM, Johnson SA and Finch CE (1994). Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience 62, 741-58
24. Yanamoto H, Kikuchi H, Ishikawa J, Shimizu Y, Sato M, Tokuriki Y, Okamoto S, Matsumoto M, Matsumoto K and Nakamura M (1993). Intravenous FUT-175 inhibits complement activation in the cerebrospinal fluid and vasospasm-related delayed ischemic neurological deficit following subarachnoid hemorrhage. Cerebral Vasospams, ed. J.M. Findley. Amsterdam: Elsevier. 431-434
25. Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza VJ, Hong H and Wisniewski HM (1990). Detection and quatitation of amyloid β-peptide with 2 monclonal antibodies. J Neurosci Res Comm 7, 113-122
26. LeVine H (1995). Thioflavine T interaction with amyloid β-sheet structures. Amyloid 2, 1-6
27. Watson MD, Roher AE, Kim KS, Spiegel K and Emmerling MR. Complement labeling of aggregated Aβ1-42 by normal human serum involves the classical and alternative pathways. Alzheimer's Disease: Biology, Diagnosis and Therapeutics, eds. K Iqbal; B Winblad, T Nishmura, M Takeda, and H Wisniewski. 1997. John Wiley & Sons Ltd. 365-373
28. Pryzdial EL and Isenman DE (1986). A reexamination of the role of magnesium in the human alternative pathway of complement. Mol Immunol 23, 87-96
29. Law SK, Lichtenberg NA and Levine RP (1980). Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci 77, 7194-7198
30. Tack BF, Harrison RA, Janatova J, Thomas ML and Prahl JW (1980). Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci 77, 5764-5768
31. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S and Fujita M (1984). Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35, 203-227
32. Emmerling MR, Spiegel K and Watson MD (1997). Inhibiting the formation of classical C3-convertase on the Alzheimer β-amyloid peptide. Immunopharm in press
33. Bradt BM, Bixby TS and Cooper NR (1996). The Alzheimer's Disease Aβ peptide generates C5a and sC5b-9 via direct activation of both complement pathways. Mol Immunol 33, 27
34. Iseman DE, Kells DIC, Cooper NR, Muller-Eberhard HJ and Pangburn MK. (1981). Nucleophilic modification of human complement protein C3: Correlation of conformational changes with acquisition of C3bi-like functional properties. Biochemistry 20, 4458-4467
35. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B and Wisniewski T (1996). The "nonamyloidogenic" p3 fragment (amyloid β17-42) is a major constituent of Down's Syndrome cerebellar preamyloid. J Biol Chem 271, 33623-33631
36. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP and Ball MJ (1994). Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269, 10987-10990
37. Gearing M, Tigges J, Mori H and Mirra SS (1996). Aβ40 is a major form of ß-amyloid in non-human primates. Neurobiol Aging 17, 903-908
38. Podlisny MB, Tolan DR and Selkoe DJ (1991). Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. Am J Pathol 138, 1423-1435
39. Webster S, Rogers J, Bradt B, Bixby T and Cooper NR (1996). Activation of the classical complement cascade by the amyloid β-peptide (Aβ) is a function of the aggregation state of Aβ Mol Immunol 33, 113
40. Velazquez P, Cribbs DH, Poulos TL, and Tenner AJ (1996). Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's Disease pathogenesis. Nat Med 3, 77-79
41. Soreghan B, Kosmoski J and Glabe C (1994). Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J Biol Chem 269, 28551-28554
42. Perlmutter LS (1994). Microvascular pathology and vascular basement membrane components in Alzheimer's disease. Mol Neurobiol 9, 33-40
43. Games D, Khan KM, Soriano FG, Keim PS, Davis DL, Bryant K and Lieberburg I (1992). Lack of Alzheimer pathology after β-amyloid protein injections in rat brain. Neurobiol Aging 13, 569-576
44. Podlisny MB, Stephenson DT, Frosch MP, Lieberburg I, Clemens JA and Selkoe DJ (1992). Synthetic amyloid beta-protein fails to produce specific neurotoxicity in monkey cerebral cortex. Neurobiol Aging 13, 561-567
45. Podlisny MB, Stephenson DT, Frosch MP, Tolan DR, Lieberburg I, Clemens JA and Selkoe DJ (1993). Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am J Pathol 142, 17-24
46. Winkler J, Connor DJ, Frautschy SA, Behl C, Waite JJ, Cole GM and Thai LJ (1994). Lack of long-term effects after β-amyloid protein injections in rat brain. Neurobiol Aging 15, 601-607
47. Frautschy SA, Baird A and Cole GM (1991). Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci 88, 8362-8366
48. Frautschy SA, Cole GM and Baird A (1992). Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol 140, 1389-1399
49. Hsaio K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F and Cole G (1996). Correlative memeory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102
50. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoys-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B and Zhao J (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527
51. Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Gotze O and Morgan BP (1995). Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 155, 4882-4889
52. Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA and Barnum SR (1995). Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J Neuroimmunol 61, 71-78
53. Pike CJ, Walencewicz AJ, Glabe CG and Cotman CW (1991). Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 207, 367-368
54. Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo Y-M and Roher AE (1996). Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 16, 6021-6037